Subjects ” General neurology
HealthDay News – Pfizer said it would meet with U.S. officials on Monday to discuss a possible approval for a third booster of its COVID-19 vaccine.
Last week, Pfizer cited data from Israel showing its vaccine is waning in preventing milder coronavirus cases as the highly contagious Delta variant is circulating in that country. However, some American scientists and health officials have warned that this data is so far only known to the company, although Pfizer plans to share it with the U.S. Food and Drug Administration, the Washington Post reported.
Pfizer also announced last week that early data suggest people’s antibody levels rose five to ten-fold after a third dose, showing the compelling need for a booster dose.
Continue reading
Only about 48 percent of the total US population is fully vaccinated, and in parts of the country where vaccination rates are lower, the highly contagious Delta variant is spreading and cases are increasing. Last week, Rochelle Walensky, MD, director of the CDC said this creates a harsh truth: Highly vaccinated parts of America are normalizing, while cases and hospitalizations in places with low vaccination rates increase.
The Washington Post article
Subjects:
COVID19 COVID19 Vaccine General Infectious Diseases General Neurology
Would you like to read more?
Please log in or register first to view this content.
Login Register
to open
Next post in General Neurology
Shut down
Include more information on Pfizer to meet with US officials about COVID-19 Booster Shot
Loading… 
Include more information on Pfizer to meet with US officials about COVID-19 Booster Shot
Loading…
Include more information on Pfizer to meet with US officials about COVID-19 Booster Shot
Loading…
Include more information on Pfizer to meet with US officials about COVID-19 Booster Shot
Loading…
Would you like to see more content from Neurology Advisor?
Register now for free to access unlimited clinical news with personalized daily tips for you, Full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Would you like to read more?
Please log in or register first to view this content.
Login Register
